Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Verona Pharma plc

Get SEC filing alerts via email and in your feed for Verona Pharma plc

VRNA

Verona Pharma plc

About Verona Pharma plc

Verona Pharma plc is a biopharmaceutical company specializing in developing and commercializing inhaled respiratory therapies. Its flagship product, Ohtuvayre (ensifentrine), is a first-in-class inhaled dual PDE3 and PDE4 inhibitor approved for COPD maintenance treatment. The company focuses on innovative treatments targeting unmet needs in respiratory diseases, leveraging strategic partnerships and a strong patent portfolio to expand into global markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Verona Pharma plc

1
1
Verona Pharma plc Verona Pharma Reports $103.1 Million Revenue and $11.9 Million Net Income in Q2 2025

Via official filing (AI summary) | 11 months ago | 0 comments

2
1
Verona Pharma plc Verona Pharma Reports $76.3 Million Revenue in Latest Quarter, Driven by Ohtuvayre Sales

Via official filing (AI summary) | about 1 year ago | 0 comments

3
1
Verona Pharma plc Verona Pharma Reports Launch of Ohtuvayre and Financial Developments for 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

4
1
Verona Pharma plc Verona Pharma Reports Financial Developments, Including Increased Cash Reserves and Revenue from Newly Launched COPD Treatment

Via official filing (AI summary) | over 1 year ago | 0 comments